The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.
Cisplatin: The first metal based anticancer drug
Abstract
Cisplatin or (SP-4-2)-diamminedichloridoplatinum(II) is one of the most potential and widely used drugs for the treatment of various solid cancers such as testicular, ovarian, head and neck, bladder, lung, cervical cancer, melanoma, lymphomas and several others. Cisplatin exerts anticancer activity via multiple mechanisms but its most acceptable mechanism involves generation of DNA lesions by interacting with purine bases on DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. However, side effects and drug resistance are the two inherent challenges of cisplatin which limit its application and effectiveness. Reduction of drug accumulation inside cancer cells, inactivation of drug by reacting with glutathione and metallothioneins and faster repairing of DNA lesions are responsible for cisplatin resistance. To minimize cisplatin side effects and resistance, combination therapies are used and have proven more effective to defect cancers. This article highlights a systematic description on cisplatin which includes a brief history, synthesis, action mechanism, resistance, uses, side effects and modulation of side effects. It also briefly describes development of platinum drugs from very small cisplatin complex to very large next generation nanocarriers conjugated platinum complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Pearson, R. G. (1963) · Journal of the American Chemical Society · doi:10.1021/ja00905a001 · Cited by 10,475
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“The detail for mechanism of cisplatin resistance remains elsewhere [99].”
BackgroundEffect of Surface Properties on Nanoparticle–Cell Interactions
Verma, A., & Stellacci, F. (2010) · Small · doi:10.1002/smll.200901158 · Cited by 2,619
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Mitochondrial control of apoptosis
Kroemer, G., Zamzami, N., & Susin, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)80014-x · Cited by 1,471
Iversen, T.-G., Skotland, T., & Sandvig, K. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.003 · Cited by 1,239
Green, D. R. (1998) · Cell · doi:10.1016/s0092-8674(00)81728-6 · Cited by 1,196
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Post‐translational modifications and activation of p53 by genotoxic stresses
Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,079
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Fuertes, M. A., Alonso, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 893
Puma is an essential mediator of p53-dependent and -independent apoptotic pathways
Jeffers, J. R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean, K. H., Han, J., Chittenden, T., Ihle, J. N., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00244-7 · Cited by 879
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Bhirde, A. A., Patel, V., Gavard, J., Zhang, G., Sousa, A. A., Masedunskas, A., Leapman, R. D., Weigert, R., Gutkind, J. S., & Rusling, J. F. (2009) · ACS Nano · doi:10.1021/nn800551s · Cited by 853
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
Youlden, D. R., Cramb, S. M., & Baade, P. D. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818020eb · Cited by 812
Le Chevalier, T., Brisgand, D., Douillard, J. Y., Pujol, J. L., Alberola, V, Monnier, A., Riviere, A., Lianes, P., Chomy, P., & Cigolari, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.360 · Cited by 811
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Galanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
Go, R. S., & Adjei, A. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.409 · Cited by 697
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 685
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Ma, P., Xiao, H., Yu, C., Liu, J., Cheng, Z., Song, H., Zhang, X., Li, C., Wang, J., Gu, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04269 · Cited by 649
Reed, J. C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd726 · Cited by 643
Molecular Mechanisms of Mammalian Global Genome Nucleotide Excision Repair
Gillet, L. C. J., & Schärer, O. D. (2006) · Chemical Reviews · doi:10.1021/cr040483f · Cited by 642 · cited 1×
“NER system excises damaged nucleotides on both strands and then synthesizes DNA to reconstitute integrity of gene [96].”
BackgroundCisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Synthetic Methods for the Preparation of Platinum Anticancer Complexes
Wilson, J. J., & Lippard, S. J. (2014) · Chemical Reviews · doi:10.1021/cr4004314 · Cited by 630
Platinum(IV) antitumour compounds: their bioinorganic chemistry
Hall, M. D., & Hambley, T. W. (2002) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00026-7 · Cited by 622
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Baudino, T. (2015) · Current Drug Discovery Technologies · doi:10.2174/1570163812666150602144310 · Cited by 611
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Cellular accumulation of the anticancer agent cisplatin: A review
Gately, D., & Howell, S. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.221 · Cited by 572
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Mechanisms of cisplatin-induced ototoxicity and prevention
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007) · Hearing Research · doi:10.1016/j.heares.2006.09.015 · Cited by 563
Knight, K. R. G., Kraemer, D. F., & Neuwelt, E. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5355 · Cited by 542
The Discovery and Development of Cisplatin
Alderden, R. A., Hall, M. D., & Hambley, T. W. (2006) · Journal of Chemical Education · doi:10.1021/ed083p728 · Cited by 532
Dai, Y., Xiao, H., Liu, J., Yuan, Q., Ma, P., Yang, D., Li, C., Cheng, Z., Hou, Z., Yang, P., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja410028q · Cited by 529
Bruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Dhar, S., Kolishetti, N., Lippard, S. J., & Farokhzad, O. C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011379108 · Cited by 513
Oxidative Stress, Toxicology, and Pharmacology of CYP2E1
Caro, A. A., & Cederbaum, A. I. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121704 · Cited by 512
Dhar, S., Daniel, W. L., Giljohann, D. A., Mirkin, C. A., & Lippard, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9071282 · Cited by 510
Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine
Farrer, N. J., Salassa, L., & Sadler, P. J. (2009) · Dalton Transactions · doi:10.1039/b917753a · Cited by 496
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
Porous Hollow Fe3O4 Nanoparticles for Targeted Delivery and Controlled Release of Cisplatin
Cheng, K., Peng, S., Xu, C., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja903300f · Cited by 438
Targeting antioxidants to mitochondria: A new therapeutic direction
Sheu, S.-S., Nauduri, D., & Anders, M. W. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.10.007 · Cited by 414
Endogenous Glutathione Conjugates: Occurrence and Biological Functions
Wang, W., & Ballatori, N. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01370-x · Cited by 413
Marty, M., Pouillart, P., Scholl, S., Droz, J. P., Azab, M., Brion, N., Pujade-Lauraine, E., Paule, B., Paes, D., & Bons, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003223221205 · Cited by 406
Cancer drug delivery in the nano era: An overview and perspectives
Li, Z., Tan, S., Li, S., Shen, Q., & Wang, K. (2017) · Oncology Reports · doi:10.3892/or.2017.5718 · Cited by 406
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Dumbbell-like Au−Fe3O4 Nanoparticles for Target-Specific Platin Delivery
Xu, C., Wang, B., & Sun, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900790v · Cited by 390
Historical review of the causes of cancer
Blackadar, C. B. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.54 · Cited by 389
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 370
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate
Dhar, S., & Lippard, S. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912276106 · Cited by 369
Clinical Perspectives on Platinum Resistance
Giaccone, G. (2000) · Drugs · doi:10.2165/00003495-200059004-00002 · Cited by 364
Cisplatin Binding Sites on Human Albumin
Ivanov, A. I., Christodoulou, J., Parkinson, J. A., Barnham, K. J., Tucker, A., Woodrow, J., & Sadler, P. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14721 · Cited by 362
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00338 · Cited by 361
Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis
Lin, Y., Ma, W., & Benchimol, S. (2000) · Nature Genetics · doi:10.1038/79102 · Cited by 353
Current status and future directions of cancer immunotherapy
Zhang, H., & Chen, J. (2018) · Journal of Cancer · doi:10.7150/jca.24577 · Cited by 345
Kris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O'Connell, J. P., Wertheim, M. S., & Kelsen, D. P. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.10.1379 · Cited by 336
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010) · International Journal of Cancer · doi:10.1002/ijc.25191 · Cited by 334
Park, G. Y., Wilson, J. J., Song, Y., & Lippard, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207670109 · Cited by 330
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
Introduction to Cancer Chemotherapeutics
Shewach, D. S., & Kuchta, R. D. (2009) · Chemical Reviews · doi:10.1021/cr900208x · Cited by 323
Selvakumaran, M., Pisarcik, D., Bao, R., Yeung, A. T., & Hamilton, T. C. (2003) · PubMed · Cited by 317
Ang, W. H., Khalaila, I., Allardyce, C. S., Juillerat-Jeanneret, L., & Dyson, P. J. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0432618 · Cited by 314
Hannon, M. J. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779122243 · Cited by 313
Oxaliplatin-Induced Damage of Cellular DNA
Woynarowski, J. M., Faivre, S., Herzig, M. C. S., Arnett, B., Chapman, W. G., Trevino, A. V., Raymond, E., Chaney, S. G., Vaisman, A., Varchenko, M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12463-7 · Cited by 310
ATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309
Min, Y., Li, J., Liu, F., Yeow, E. K. L., & Xing, B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308834 · Cited by 309
Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man
Dentino, M. E., Luft, F. C., Yum, M. N., Williams, S. D., & Einhorn, L. H. (1978) · Cancer · Cited by 305
Why develop photoactivated chemotherapy?
Bonnet, S. (2018) · Dalton Transactions · doi:10.1039/c8dt01585f · Cited by 297
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Baik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Preclinical Perspectives on Platinum Resistance
Kelland, L. R. (2000) · Drugs · doi:10.2165/00003495-200059004-00001 · Cited by 280
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Brozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
The state-of-play and future of platinum drugs
Apps, M. G., Choi, E. H. Y., & Wheate, N. J. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0237 · Cited by 256
Drug Delivery Strategies for Platinum-Based Chemotherapy
Browning, R. J., Reardon, P. J. T., Parhizkar, M., Pedley, R. B., Edirisinghe, M., Knowles, J. C., & Stride, E. (2017) · ACS Nano · doi:10.1021/acsnano.7b04092 · Cited by 247
Cisplatin Overdose: Toxicities and Management
Tsang, R. Y., Al-Fayea, T., & Au, H.-J. (2009) · Drug Safety · doi:10.2165/11316640-000000000-00000 · Cited by 235
ASTOLFI, L., GHISELLI, S., GUARAN, V., CHICCA, M., SIMONI, E., OLIVETTO, E., LELLI, G., & MARTINI, A. (2013) · Oncology Reports · doi:10.3892/or.2013.2279 · Cited by 234
The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae
Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1154 · Cited by 232
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy
Qi, S.-S., Sun, J.-H., Yu, H.-H., & Yu, S.-Q. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1410256 · Cited by 218
Nanoparticle formulations of cisplatin for cancer therapy
Duan, X., He, C., Kron, S. J., & Lin, W. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1390 · Cited by 216
7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS
Casini, A., Wai-Yin Sun, R., & Ott, I. (2018) · Metallo-Drugs: Development and Action of Anticancer Agents · doi:10.1515/9783110470734-007 · Cited by 215
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
He, Q., Liang, C. H., & Lippard, S. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100108697 · Cited by 209
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
Lynch, H. T., Casey, M. J., Snyder, C. L., Bewtra, C., Lynch, J. F., Butts, M., & Godwin, A. K. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.02.004 · Cited by 208
Ishikawa, T., Wright, C. D., & Ishizuka, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62016-8 · Cited by 206
Ciccarelli, R. B., Solomon, M. J., Varshavsky, A., & Lippard, S. J. (1985) · Biochemistry · doi:10.1021/bi00347a005 · Cited by 205
Trans-Platinum Complexes in Cancer Therapy
Coluccia, M., & Natile, G. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007779314080 · Cited by 202
Simvastatin attenuates cisplatin-induced kidney and liver damage in rats
İşeri, S., Ercan, F., Gedik, N., Yüksel, M., & Alican, İ. (2007) · Toxicology · doi:10.1016/j.tox.2006.11.073 · Cited by 202
Cisplatin-Induced Hepatotoxicity Is Enhanced by Elevated Expression of Cytochrome P450 2E1
Lu, Y., & Cederbaum, A. I. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj031 · Cited by 202
Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Achkar, I. W., Abdulrahman, N., Al-Sulaiti, H., Joseph, J. M., Uddin, S., & Mraiche, F. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1471-1 · Cited by 199
Sedletska, Y., Giraud-Panis, M.-J., & Malinge, J.-M. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053765967 · Cited by 195
Trends of Gold Nanoparticle-based Drug Delivery System in Cancer Therapy
Ajnai, G., Chiu, A., Kan, T., Cheng, C.-C., Tsai, T.-H., & Chang, J. (2014) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2014.10.015 · Cited by 194
Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial
Pace, A., Giannarelli, D., Galiè, E., Savarese, A., Carpano, S., Della Giulia, M., Pozzi, A., Silvani, A., Gaviani, P., Scaioli, V., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d5279e · Cited by 191
Platinum coordination compounds with potent anticancer activity
Deo, K. M., Ang, D. L., McGhie, B., Rajamanickam, A., Dhiman, A., Khoury, A., Holland, J., Bjelosevic, A., Pages, B., Gordon, C., et al. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.11.014 · Cited by 191
Raveendran, R., Braude, J. P., Wexselblatt, E., Novohradsky, V., Stuchlikova, O., Brabec, V., Gandin, V., & Gibson, D. (2016) · Chemical Science · doi:10.1039/c5sc04205d · Cited by 183
Pt(IV) complexes as prodrugs for cisplatin
Shi, Y., Liu, S.-A., Kerwood, D. J., Goodisman, J., & Dabrowiak, J. C. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.10.012 · Cited by 179
Ixr1, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin
Brown, S. J., Kellett, P. J., & Lippard, S. J. (1993) · Science · doi:10.1126/science.8342024 · Cited by 178
Cong, Y., Xiao, H., Xiong, H., Wang, Z., Ding, J., Li, C., Chen, X., Liang, X., Zhou, D., & Huang, Y. (2018) · Advanced Materials · doi:10.1002/adma.201706220 · Cited by 178
Recent progress in polymer-based platinum drug delivery systems
Xiao, H., Yan, L., Dempsey, E. M., Song, W., Qi, R., Li, W., Huang, Y., Jing, X., Zhou, D., Ding, J., et al. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.004 · Cited by 172
Ueber die Einwirkung des Ammoniaks auf Platinchlorür
Peyrone, M. (1844) · Justus Liebigs Annalen der Chemie · doi:10.1002/jlac.18440510102 · Cited by 168
Platinum(IV) Prodrugs – A Step Closer to Ehrlich's Vision?
Kenny, R. G., Chuah, S. W., Crawford, A., & Marmion, C. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201601278 · Cited by 168
Satraplatin: leading the new generation of oral platinum agents
Bhargava, A., & Vaishampayan, U. N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903362437 · Cited by 167
Lynch, E. D., Gu, R., Pierce, C., & Kil, J. (2005) · Hearing Research · doi:10.1016/j.heares.2004.08.002 · Cited by 167
Davies, M. S., Berners-Price, S. J., & Hambley, T. W. (2000) · Inorganic Chemistry · doi:10.1021/ic000847w · Cited by 165
Kumar, A., Huo, S., Zhang, X., Liu, J., Tan, A., Li, S., Jin, S., Xue, X., Zhao, Y., Ji, T., et al. (2014) · ACS Nano · doi:10.1021/nn500152u · Cited by 162
Usanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 162
Towards Antitumor Active trans‐Platinum Compounds
Aris, S. M., & Farrell, N. P. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200801118 · Cited by 160
Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity
Martinho, N., Santos, T. C. B., Florindo, H. F., & Silva, L. C. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2018.01898 · Cited by 160
Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts
Moggs, J. G., Szymkowski, D. E., Yamada, M., Karran, P., & Wood, R. D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.3.480 · Cited by 158
Trans geometry in platinum antitumor complexes
Kalinowska‐Lis, U., Ochocki, J., & Matlawska‐Wasowska, K. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2007.07.015 · Cited by 157
Wagner, J. M., & Karnitz, L. M. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055178 · Cited by 157
Recognition and repair of DNA-cisplatin adducts.
Woźniak, K., & Błasiak, J. (2002) · Acta Biochimica Polonica · doi:10.18388/abp.2002_3768 · Cited by 155
Dreyfuss, A. I., Clark, J. R., Fallon, B. G., Posner, M. R., Norris, C. M., & Miller, D. (1987) · Cancer · Cited by 155
Hainsworth, J. D., Harvey, W. H., Pendergrass, K. B., et al. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.721 · Cited by 154
Inorganic nanocarriers for platinum drug delivery
Ma, P., Xiao, H., Li, C., Dai, Y., Cheng, Z., Hou, Z., & Lin, J. (2015) · Materials Today · doi:10.1016/j.mattod.2015.05.017 · Cited by 151
Makin, G., Corfe, B. M., Griffiths, G. J., Thistlethwaite, A., Hickman, J. A., & Dive, C. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6306 · Cited by 151
Selection of agents for prevention of cisplatin-induced hepatotoxicity
Liao, Y., Lu, X., Lu, C., Li, G., Jin, Y., & Tang, H. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.01.001 · Cited by 140
Dexeus, F. H., Logothetis, C. J., Sella, A., Amato, R. J., Kilbourn, R. G., Fitz, K., & Striegel, A. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38069-2 · Cited by 140
Sengupta, P., Basu, S., Soni, S., Pandey, A., Roy, B., Oh, M. S., Chin, K. T., Paraskar, A. S., Sarangi, S., Connor, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203129109 · Cited by 138
Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Drbohlavová, J., Chomoucká, J., Adam, V., Ryvolová, M., Eckschlager, T., Hubálek, J., & Kizek, R. (2013) · Current Drug Metabolism · doi:10.2174/1389200211314050005 · Cited by 136
Yang, Y., Adebalı, O., Wu, G., Selby, C. P., Chiou, Y., Rashid, N. U., Hu, J., Hogenesch, J. B., & Sancar, A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804493115 · Cited by 134
Cheng, Z., Dai, Y., Kang, X., Li, C., Huang, S., Lian, H., Hou, Z., Ma, P., & Lin, J. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.029 · Cited by 132
Eastman, A. R. (2016) · Oncotarget · doi:10.18632/oncotarget.12673 · Cited by 129
Trimmer, E. E., & Essigmann, J. M. (1999) · Essays in Biochemistry · doi:10.1042/bse0340191 · Cited by 127
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
New-Generation Platinum Agents for Solid Tumors
Shah, N. A., & Dizon, D. S. (2009) · Future Oncology · doi:10.2217/14796694.5.1.33 · Cited by 126
Li, J., Lyv, Z., Li, Y., Liu, H., Wang, J., Zhan, W., Chen, H., Chen, H., & Li, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.074 · Cited by 123
Saad, S. Y., Najjar, T. A. O., & Alashari, M. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04127.x · Cited by 123
Craig, G. E., Brown, S. D., Lamprou, D. A., Graham, D., & Wheate, N. (2012) · Inorganic Chemistry · doi:10.1021/ic202197g · Cited by 122
Cumulative toxicities from cisplatin therapy and current cytoprotective measures
Cvitkovic, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90061-5 · Cited by 119
Photoactivated platinum-based anticancer drugs
Imran, M., Ayub, W., Butler, I. S., & Zia-Ur-Rehman (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.08.009 · Cited by 114
Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery
Guven, A., Rusakova, I. A., Lewis, M. T., & Wilson, L. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.060 · Cited by 111
Novel Concepts in the Development of Platinum Antitumor Drugs
Fuertes, M. A., Castilla, J., Alonso, C., & Perez, J. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023353958 · Cited by 105
Lin, C., Yeh, H.-H., Huang, W.-L., Yan, J.-J., Lai, W., Su, W., Chen, H. H. W., & Su, W. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0244oc · Cited by 104
Cisplatin Damage: Are DNA Repair Proteins Saviors or Traitors to the Cell?
Zorbas, H., & Keppler, B. K. (2005) · ChemBioChem · doi:10.1002/cbic.200400427 · Cited by 103
Interaction with p53 Enhances Binding of Cisplatin-modified DNA by High Mobility Group 1 Protein
Imamura, T., Izumi, H., Nagatani, G., Ise, T., Nomoto, M., Iwamoto, Y., & Kohno, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008143200 · Cited by 102
Cisplatin therapy in recurrent childhood brain tumors.
Khan, A. B., D’Souza, B. J., Wharam, M. D., Champion, L. A., Sinks, L. F., Woo, S. Y., McCullough, D. C., & Leventhal, B. G. (1982) · PubMed · Cited by 101
Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation
Damia, G. L. M., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D’Incalci, M., & Broggini, M. (2001) · Neoplasia · doi:10.1038/sj.neo.7900122 · Cited by 97
Gold nanorods for platinum based prodrug delivery
Min, Y., Mao, C., Xu, D., Wang, J., & Liu, Y. (2010) · Chemical Communications · doi:10.1039/c0cc03108a · Cited by 95
Cisplatin Cytotoxicity: DNA and Plasma Membrane Targets
Rébillard, A., Lagadic‐Gossmann, D., & Dimanche‐Boitrel, M. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242903 · Cited by 94
Tsimberidou, A. M., Braiteh, F., Stewart, D. J., & Kurzrock, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6018 · Cited by 93
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.003 · Cited by 91
Li, J., Yap, S. Q., Chin, C. F., Tian, Q., Yoong, S. L., Pastorin, G., & Ang, W. H. (2012) · Chemical Science · doi:10.1039/c2sc01086k · Cited by 91
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
Li, X., Liu, Y., & Tian, H. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/8276139 · Cited by 90
He, H., Xiao, H., Kuang, H., Xie, Z., Chen, X., Jing, X., & Huang, Y. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.02.014 · Cited by 89
Uchiumi, T., Hinoshita, E., Haga, S., Nakamura, T., Tanaka, T., Toh, S., Furukawa, M., Kawabe, T., Wada, M., Kagotani, K., et al. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9546 · Cited by 86
Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters
Hu, X., Li, F., Noor, N., & Ling, D. (2017) · 中国科学通报:英文版 · doi:10.1016/j.scib.2017.03.008 · Cited by 86
Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents
Xiao, H., Qi, R., Li, T., Awuah, S. G., Zheng, Y., Wei, W., Kang, X., Song, H., Wang, Y., Yu, Y., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12108 · Cited by 84
Cisplatin in the Treatment of Cancer
Wiltshaw, E. (1979) · Platinum Metals Review · doi:10.1595/003214079x2339098 · Cited by 84
Dimery, I. W., Legha, S. S., Shirinian, M. H., & Hong, W. K. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1056 · Cited by 83
Testis-specific HMG-domain protein alters the responses of cells to cisplatin
Zamble, D. B., Mikata, Y., Eng, C. H., Sandman, K. E., & Lippard, S. J. (2002) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(02)00472-5 · Cited by 83
Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines
Kakar, S. S., Jala, V. R., & Fong, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.047 · Cited by 83
Platinum Anticancer Drugs and Photochemotherapeutic Agents: Recent Advances and Future Developments
Shaili, E. (2014) · Science Progress · doi:10.3184/003685014x13904811808460 · Cited by 81
Cellular interactions of platinum drugs
Wexselblatt, E., Yavin, E., & Gibson, D. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.07.013 · Cited by 79
Ardizzoni, A., Rosso, R., Fusco, V., Pennucci, M. C., Santi, L., Salvati, F., Cinquegrana, A., Palma, M. D., Serrano, J., Soresi, E., et al. (1991) · Cancer · Cited by 78
Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
Meng, F., Sun, G., Zhong, M., Yu, Y., & BREWER, M. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.10 · Cited by 77
Nessa, M. U., Beale, P. J., Chan, C., Yu, J. Q., & Huq, F. (2011) · PubMed · Cited by 76
Kosmas, C., Tsavaris, N. B., Malamos, N. A., Vadiaka, M., & Koufos, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.119 · Cited by 73
Xing, R., Wang, X., Zhang, C., Wang, J., Zhang, Y., Song, Y., & Guo, Z. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm11369k · Cited by 72
Nakayama, K., Miyazaki, K., Kanzaki, A., Fukumoto, M., & Takebayashi, Y. (2001) · Oncology Reports · doi:10.3892/or.8.6.1285 · Cited by 71
Liposomes, a promising strategy for clinical application of platinum derivatives
Zalba, S., & Garrido, M. J. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.778240 · Cited by 69
Cited by
Zafar, A., Khatoon, S., Khan, M. J., Abu, J., & Naeem, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-02198-8 · Cited by 565
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Chen, S.-H., & Chang, J.-Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174136 · Cited by 428
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Metadata
- Authors
- Ghosh, S.
- Venue
- Bioorganic Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 88
- Pages
- 102925
- ISSN
- 0045-2068 (ISSN-L)
- OpenAlex
- W2937766145
- Cited by
- 1,751
- References
- 233
- FWCI
- 56.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.